Impact Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Impact Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.04M	Sell	1,980 -66	-3%	-$33.8K	0.28%	80
2026 Q2	$1.02M	Sell	2,046 -117	-5%	-$51.9K	0.28%	92
2026 Q1	$966K	Sell	2,163 -63	-3%	-$29.4K	0.29%	77
2025 Q4	$1.01M	Buy	2,226 +75	+3%	+$32.3K	0.3%	71
2025 Q3	$842K	Buy	2,151 +12	+0.6%	+$5.02K	0.25%	81
2025 Q2	$952K	Sell	2,139 -337	-14%	-$155K	0.31%	72
2025 Q1	$1.2M	Buy	2,476 +232	+10%	+$108K	0.43%	60
2024 Q4	$904K	Buy	+2,244	New	+$1.04M	0.32%	77

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Impact Capital Partners's VRTX Position: Q3 2026 in Review

Impact Capital Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q3 2026, selling an estimated $33.8K and leaving 1,980 shares worth $1.04M. The position accounts for 0.28% of the portfolio, ranked #80.

Impact Capital Partners first reported a position in VRTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.2M in Q1 2025. 1,356 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Impact Capital Partners held 1,980 shares of Vertex Pharmaceuticals worth $1.04M as of Q3 2026.
Impact Capital Partners sold 66 Vertex Pharmaceuticals shares in Q3 2026, an estimated $33.8K.
Vertex Pharmaceuticals made up 0.28% of Impact Capital Partners's portfolio in Q3 2026, its #80 holding.
Impact Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Impact Capital Partners's Vertex Pharmaceuticals position peaked at $1.2M in Q1 2025.
1,356 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Impact Capital Partners's 13F filing for Q3 2026, filed 22 Oct 2026.